1. Home
  2. IDR vs DSGN Comparison

IDR vs DSGN Comparison

Compare IDR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$38.02

Market Cap

378.0M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.77

Market Cap

418.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDR
DSGN
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
418.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
IDR
DSGN
Price
$38.02
$9.77
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$17.50
$13.50
AVG Volume (30 Days)
425.5K
538.4K
Earning Date
11-12-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
52.70
N/A
EPS
0.73
N/A
Revenue
$35,424,313.00
N/A
Revenue This Year
$21.91
N/A
Revenue Next Year
$5.47
N/A
P/E Ratio
$52.74
N/A
Revenue Growth
61.35
N/A
52 Week Low
$9.67
$2.60
52 Week High
$54.70
$10.31

Technical Indicators

Market Signals
Indicator
IDR
DSGN
Relative Strength Index (RSI) 55.63 71.98
Support Level $31.22 $8.58
Resistance Level $39.88 $9.85
Average True Range (ATR) 3.18 0.66
MACD 0.50 0.13
Stochastic Oscillator 68.52 86.62

Price Performance

Historical Comparison
IDR
DSGN

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: